Clinical Trial Alert: Orion Pharma Seeks Participants for a Phase 3 ALS Study

Researchers at Orion Pharma are looking for participants with ALS (amyotrophic lateral sclerosis) to participate in the REFALS Phase 3 study. The study is designed to help researchers evaluate the effects of oral levosimendan (ODM-109) on respiratory function in patients with ALS. Participants will be randomized to receive either levosimendan or placebo to determine whether . . .

Read More

On May 11, Drink One for Dane

On May 11, your daily cup of coffee can boost more than your energy — it can also bolster MDA’s quest to end ALS. For 12 years, Dutch Bros. Coffee has supported MDA through Drink One for Dane Day, a fundraiser launched in 2007 in honor of Dutch Bros. co-founder Dane Boersma, who was diagnosed . . .

Read More

MDA and ALS ONE Work to Advance ALS Biomarker Research

MDA has awarded a human clinical trial grant totaling $750,000 to ALS ONE to explore the potential for a type of imaging called positron emission tomography (PET) to measure inflammation in the brain that could serve as a biomarker for ALS. ALS ONE is an alliance between four institutional leaders in ALS treatment development: Massachusetts . . .

Read More